Adrenocortical CarcinomaTreatment Market: Regional Dynamics
Regional segmentation of theglobal AdrenocorticalCarcinoma Treatment Market by Coherent Market Insights comprises NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa. NorthAmerica is expected to hold a dominant position in the global adrenocorticalcarcinoma treatment market over the forecast period, owing to rise inprevalence of the disease and presence of key players that are focusing ondeveloping novel products, followed by Europe, the next dominatingadrenocortical carcinoma treatment market. According to the National Institutesof Health Office of Rare Diseases Research, the incidence rate of adrenalcancer is about 600 new cases per year in the U.S. Moreover, organizations suchas the University of Michigan Rogel Cancer Center are involved in stem cellresearch, to advance treatment in adrenal cancer.
Latin America is expected to gainsignificant traction in the forecast period, owing to higher incidence rate ofthe condition in Brazil. According to the survey ACC C.U.R.E. Organization,adrenal cancer in Brazil is 15 times more prevalent than any other countries inthe world, attributed to high prevalence of mutation of a single gene TP53.Also, according to the Endocrine Society, 2014, the incidence during childhoodis 2.9 to 4.2 per million per year in Brazil compared with an estimatedincidence of 0.2 to 0.3 per million children per year worldwide. Moreover, theUniversity of Michigan has been collaborating with the Adrenal Cancer Group inSao Paulo to bring about the advancements in adrenal cancer research, thusproviding better clinical outcomes for patients in the region.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1551
Adrenocortical carcinoma is arare cancer affecting the outer layer of the adrenal glands, which areresponsible for producing certain hormones and maintaining optimum bloodpressure levels. Adrenocortical carcinoma is relatively frequent in childrencompared to other cancers, although the cancer may also affect adults. The mostcommon symptoms of adrenocortical carcinoma include abdominal pain,hypertension, weight gain, and frequent urination, which are mainly caused dueto tumors causing excess secretion of hormones from the adrenal glands. Mitotaneis the only drug approved by the U.S. Food and Drug Administration (FDA) andEuropean Medicine Executive Agency (EMEA) for treatment of metastaticadrenocortical carcinoma. According to the study by HealthLine Media, 2017,about 5-10% of the adrenal tumors are malignant. Diagnosis of adrenocorticalcarcinoma is based on urine tests, dexamethasone suppression test for detectingabnormal levels of cortisol, which is the hormone released by the adrenalglands. Also, a wide number of imaging devices are used for diagnoses of thedisease, which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding forfaster disease identification that aids the doctors to decide for furthertreatments.
Adrenocortical Carcinoma TreatmentMarket: Market Dynamics
Increasing incidence ofadrenocortical carcinoma associated with genetic disorders is a major factoraugmenting growth of the adrenocortical carcinoma treatment market. Accordingto the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidenceof adrenocortical carcinoma ranges between 40-50 years, where women are 55–60%more likely to get affected with a ratio of ratio 1.5:1. The study also statesthat adrenocortical carcinoma is a rare and highly aggressive malignancy withan annual incidence of 0.05–0.2% or 1-2 cases per million population globally.Also, inherited disorders such as Li-Fraumeni syndrome (LFS),Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked withincreasing incidence of adrenocortical carcinoma. According to the survey byEndocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3%to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. Moreover,according to the study by Medscape, 2017, adrenocortical carcinoma accountedfor 0.02-0.2% of all cancer-related deaths, globally.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/adrenocortical-carcinoma-treatment-market-1551
Moreover, number of clinicaltrials are increasing for different chemotherapeutics by various organizationsand manufacturers. For instance, Millendo Therapeutics, Inc., initiated thePhase 1 trial for ATR-101 in 2013 to treat adrenocortical carcinoma. Also, theNational Cancer Institute initiated a Phase 2 trial for Phase II trial ofCisplatin and sodium thiosulfate for surgical resection and HeatedIntraperitoneal Peritoneal Chemotherapy (HIPEC) for adrenocortical carcinoma.Also, in March 2018, the University of Colorado Anschutz Medical Campuspresented new models to identify genetic targets and test promising treatmentsin adrenocortical carcinoma at the ENDO Conference, thus exploring newtherapeutic options for the patients.
Adrenocortical Carcinoma TreatmentMarket: Competitive Analysis
Manufactures are focused onlaunching novel therapeutic products for treatment of these rare diseases, thusaccelerating market growth. For instance, in 2017, the FDA approvedimmunotherapy drug Keytruda (Pembrolizumab), the first anti-PD-1 (programmeddeath receptor-1) therapy, developed by Merck & Co., indicated for advancedadrenocortical carcinoma.
Key players operating in theglobal adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneICLtd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and OrphagenPharmaceuticals, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1551
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offering action-readysyndicated research reports, custom market analysis, consulting services, andcompetitive analysis through various recommendations related to emerging markettrends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
